Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Shots:Sangamo has granted Eli Lilly global exclusive license of STAC-BBB for one initial CNS target, with an option to add up to 4 more targets upon payment of additional license fees, allowing IV delivery of Lilly’s genomic medicines for CNS diseasesAs per the deal, Lilly will handle R&D, regulatory activities, manufacturing, & global…

ByRidhi RastogiApril 4, 2025

NEWS

Pfizer Teminates the Deal to Develop Giroctocogene Fitelparvovec for Hemophilia A with Sangamo Therapeutics

Shots:Sangamo regains rights to giroctocogene fitelparvovec (gene therapy for hemophilia A) as Pfizer ends their collaboration (effective Apr 21, 2025) & decids not to file BLA or MAA to pursue commercialization. Sangamo plans to seek a new partner The drug is in P-III (AFFINE) trial involving 75 adult males with severe hemophilia A…

BySenior EditorJanuary 1, 2025

VIEWPOINTS

Bettina Cockroft, SVP & CMO at Sangamo Therapeutics Shares Insights from the Positive P-I/II Data for Fabry Disease Treatment

Shots:Bettina gave the details of the study design and shared the preliminary results from the P-I/II STAAR clinical study evaluating ST-920. The data were presented in an oral presentation at the 29th Congress of the European Society of Gene & Cell Therapy 2022 She also talked about enzyme replacement therapy (ERT) which is currently used for the…

BySenior EditorApril 24, 2023

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Pfizer Teminates the Deal to Develop Giroctocogene Fitelparvovec for Hemophilia A with Sangamo Therapeutics

Bettina Cockroft, SVP & CMO at Sangamo Therapeutics Shares Insights from the Positive P-I/II Data for Fabry Disease Treatment

Contact US

OUR INFORMATION

FOLLOW US